Skip to main content
Article
CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study
The Journal of Rheumatology (2018)
  • Philip J. Mease, University of Washington
  • Slawomir Jeka, Janssen Pharmaceutica
  • Juan Jose Jaller, Universiti Malaysia Kelantan
  • Tasanee Kitumnuaypong, Metropolitan University
  • Worawit Louthrenoo, Chiang Mai University
  • Herman Mann, Chiang Mai University
  • Galina Matsievskaia
  • Enrique R. Soriano, Hospital Italiano de Buenos Aires
  • Bin Jia, Hospital Italiano de Buenos Aires
  • Caihong Wang, Janssen Pharmaceutica
  • Jing Nie
  • Elizabeth Hsia, University of Pennsylvania
Publication Date
January 1, 2018
DOI
10.3899/jrheum.161238
Citation Information
Philip J. Mease, Slawomir Jeka, Juan Jose Jaller, Tasanee Kitumnuaypong, et al.. "CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study" The Journal of Rheumatology Vol. 45 Iss. 1 (2018) p. 22 - 31
Available at: http://works.bepress.com/philip-mease/24/